FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely peptides which can find application for metabolic syndrome correction.
EFFECT: what is presented is an agent for metabolic syndrome correction representing the tripeptide L-lysyl-L- glutamyl -L-tryptophane.
3 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC AGENT | 2007 |
|
RU2372923C2 |
| HYPOLIPIDEMIC AGENT | 2008 |
|
RU2392933C2 |
| AGENT POSSESSING HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC ACTIVITY | 2015 |
|
RU2598347C1 |
| TETRAPEPTIDE REGULATING GLUCOSE LEVEL IN DIABETES MELLITUS, PHARMACOLOGICAL AGENT BASED ON THEREOF AND METHOD FOR ITS APPLYING | 2003 |
|
RU2242241C1 |
| AGENT WITH HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC ACTION | 2008 |
|
RU2372897C1 |
| AGENT WITH HYPOLIPIDEMIC ACTIVITY | 2004 |
|
RU2268714C1 |
| LIPID-CORRECTING AGENT OF SEAWEED | 2021 |
|
RU2767908C1 |
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| METHOD OF MODELING NON-ALCOHOLIC STEATOHEPATITIS IN RATS | 2009 |
|
RU2394281C1 |
| USE OF RHODANINE DERIVATIVE 3-(2-PHENYLETHYL)-2-THIOXO-1,3 THIAZOLIDIN-4-ONE FOR CORRECTION OF METABOLIC DISORDERS | 2019 |
|
RU2768171C2 |
